Management
Slider

Daniel G. Chain, PhD – President and Chief Executive Officer

Our company is led by Daniel G. Chain, PhD, who is the inventor of the patents underlying TBL-100.  Dr. Chain is a seasoned biotechnology executive and scientist entrepreneur dedicated to the discovery and development of therapeutics for the treatment of neurodegenerative diseases. For more than 20 years, he has established and managed companies in the neurodegeneration field, and his patented innovations helped enable the development of several monoclonal antibodies tested in late stage clinical trials for Alzheimer’s disease and related indications by global pharmaceutical companies. In addition, Dr. Chain spearheaded the development of a clinical-stage compound currently under development for Friedreich’s Ataxia by Intellect Neurosciences, and a first-in-class clinical stage small molecule compound, itanapraced, being developed for Parkinson’s disease by CERESPIR where Dr. Chain is also engaged.  Dr. Chain trained as a biochemist and molecular neurobiologist having obtained his PhD from the Weizmann Institute of Sciences in Israel and subsequently trained as a researcher at Columbia College of Physicians and Surgeons in New York.

Paul Brennan – VP Business Development

Mr. Brennan brings 30 years of experience in building and leading pharmaceutical and biotechnology companies in the United States, Europe and Canadawith a strong track-record in product development, commercial development, partnering and licensing transactions. Mr. Brennancurrently heads his own consulting practise, Pacific BioPartners, and has previously been employed in senior management roles at AnorMED, Aspreva, Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.) and Aquinox.  In past roles Mr. Brennan contributed to the sale of Aspreva Pharmaceuticals to Vifor Pharma Ltd. for $915 million, the sale of AnorMED Inc. to Genzyme Corp. for $580 million and the merger of Tekmira and Oncore to create Arbutus (leading to combined market cap of over $1 Billion after the merger). Mr. Brennan also served in senior business development and regulatory affairs roles with AstraZeneca PLC, operating in Sweden, the United Kingdom and Canada.